GHRS (GH Research) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

GH Research PLC (GHRS) is a biotech startup with no current sales developing innovative psychotropic agents. The company's EV/EBITDA chart reflects a balance of market expectations, where the 0.00 mark serves as the current indicator. The project utilizes an asset-light model with contract manufacturing in Europe. Stability is ensured by a cohesive team of scientists demonstrating zero staff turnover due to high autonomy.

GHRS (GH Research plc) Company Value to EBITDA history from 11/23/2025 to 11/12/2026

Comprehensive metric breakdowns and analytics for ghres.com (GHRS)

- market price and analyst price targets:

Price Chart GH Research Corp|GHRS - Forecast Levels Chart

- business market valuation indicators:

Market Value GH Research Group|GHRS - Company Buyout Price

- book value of equity indicators:

Accounting Value per Share GH Research|GHRS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio ghres.com|GHRS - Cumulative Company Assets

- company liabilities and liquidity data:

- net income and valuation multiples indicators:

GHRS - Final Profit|Expected Profit GH Research PLC|GHRS - Company Value to Net Income|Forward P/E Multiple GH Research PLC|GHRS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GH Research Group|GHRS - Operating income before deduction of amortization|Net earnings per share (EPS TTM) GH Research|GHRS - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth ghres.com|GHRS - Earnings growth in current year|Net earnings per share growth forecast for next year GH Research PLC

Initial company analysis:GH Research Corp GHRS

This indicator determines the ratio of total enterprise value to operating profit before interest and taxes, allowing for an asset valuation that accounts for debt load. By analyzing the current EV/EBITDA valuation level, an investor can identify the undervaluation of GH Research PLC (GHRS), given the company's future high margins and pricing power derived from the uniqueness of its 5-MeO-DMT therapy for treatment-resistant depression.

Main competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alkermes Inc. ALKS|AVDL (Avadel Corp) - Company Value to Operating Income Before Depreciation Ratio|ATAI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio mindmed.co MNMD|CMPS (COMPASS Pathways) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA LB Pharmaceuticals, Inc. (LBRX)|DRUG (Bright Minds Biosciences Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Vanda (VNDA)|EV/EBITDA Multiple CYBN|ANRO (altoneuroscience.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NRx Pharmaceuticals, Inc. NRXP|Cingulate Inc (CING) - Company Value to EBITDA|Silo Pharma - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple China Pharma Holdings (CPHI)|CMND: EV/EBITDA Multiple|pacificbayminerals.com - Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio SPRC|SEEL: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virpax Pharmaceuticals (VRPX)|KRTX (Karuna Pharma) - Business Value to Operating Income Before Depreciation